Clinical Trial Update: BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for BI-1910 as a single agent and in combination with pembrolizumab in advanced solid tumors, including non-small cell lung cancer, with P…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• BI-1910
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: BioInvent International AB | Conditions: Solid Tumors, Non Small Cell Lung Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING